

NC-MEDI-CAPS LIMITED

Regd. Office and works:

Mhow - Neemuch Road, Sector 1, CIN: L70100MP1983PLC002231
Pithampur - 454775, Dist. Dhar
Madhya Pradesh, India

Ph:- 07292-256205

Fax:- 0731-4041435

E mail:- investors@medicaps.com

Website:- www.medicaps.com

MCL/SE/2021-2022

Date: 10th November, 2021

Online filing at: www.listing.bseindia.com

To,
The General Manager
DCS-CRD
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street Fort, Mumbai – 400001 (M.H.)

SUBJECT: SUBMISSION OF THE STANDALONE AND CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER/HALF YEAR ENDED ON 30TH SEPTEMBER, 2021 AS PER REGULATION 33 OF SEBI (LODR) REGULATIONS, 2015.

Ref: MEDI-CAPS LIMITED (BSE Scrip Code: 523144, ISIN: INE442D01010)

Dear Sir/Madam,

This is in Continuation of our letter no. MCL/BM/SE/2021-2022 dated 1st Nov., 2021 regarding information of Board Meeting for consideration and approval of Standalone as well as Consolidated Un-Audited Financial Results for the Quarter/Half Year ended on 30th September, 2021.

In compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to submit the Un-audited Standalone and Consolidated Financial Results for the quarter as well as half year ended 30th September, 2021 duly approved by the Board at its meeting held today i.e. 10th November, 2021 along with Limited Review Report given by the Statutory Auditors of the Company, as required under the above said Regulations.

Further, pursuant to Regulation 33(3)(f) and (g) of the Listing Regulations, we have also enclosed Statements of Assets and Liabilities and the Statement of Cash flow in the prescribed format for the half year ended 30th September, 2021.

Further, copy of Un-Audited Financial Statements shall also be submitted in XBRL mode within 24 hours from the conclusion of Board Meeting.

The above results will be published in Hindi (vernacular) and widely circulated English Newspaper.

You are requested to please take on record the aforesaid Unaudited Financial Results along with Limited review Report for your records and reference.

Thanking You,

Yours Faithfully,

For, **MEDI-CAPS LIMITED**

ALOK K GARG

MANAGING DIRECTOR

DIN: 00274321



Encl.: Unaudited Standalone and Consolidated Financial Results along with limited review report for quarter ended 30th September, 2021;

Corporate Office: 201, Pushpratna Paradise 9/5 New Palasiya,

Opposite UCO Bank Indore (M.P.) 452001

Contact No: 0731-4028148


LIMITED REVIEW REPORT ON UNAUDITED STANDALONE QUARTERLY FINANCIAL RESULTS OF MEDI-CAPS LIMITED

To,
THE BOARD OF DIRECTORS OF
MEDI-CAPS LIMITED

1. We have reviewed the accompanying statement of unaudited standalone financial results of MEDI-CAPS LIMITED ("the Company") for the quarter and half year ended 30th September ,2021 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July 2016 & CIR/CFD/CMD1/44/2019 dated 29th March 2019.

This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 Interim financial reporting "IND AS 34" prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review.


2. We conducted our review of the statement in accordance with the Standard on review engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited Financial Results, prepared in accordance with the aforesaid Indian Accounting Standards and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.




4. On 21st Nov., 2019, the company announced to permanently discontinue Company's operations related to production/manufacturing of Hard Gelatin Capsule Shell in the plant situated at Mhow - Neemuch Road, Sector 1, Pithampur - 454775, Distt. Dhar. The discontinuation is consistent with the Company's long-term strategy to focus its activities in the areas of Real Estate Business and to divest unrelated activities. Accordingly, Loss for the quarter ended September 30, 2021 is from discontinuing operation of Rs 4.03 lakhs.
5. Our conclusion on the Statement is not modified in respect of the above matter.

Place: Indore
Date: 10/11/2021
UDIN: 21429040AAAAGO1406

For: Rawka & Associates
(Chartered Accountants)




Venus Rawka
(Partner)
M. No. 429040
FRN: 021606C

Independent Auditor's Review Report On Consolidated Unaudited Quarterly and year to date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

**TO THE BOARD OF DIRECTORS OF
Medi-Caps Limited**

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Medi-Caps Limited** and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit/(loss) after tax and total comprehensive income / loss of its subsidiary for the quarter and half year ended 30/09/2021 and for the period from 01/07/2021 to 30/09/2021, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July 2016 & CIR/CFD/CMD1/44/2019 dated 29th March 2019. Attention is drawn to the fact that the consolidated figures for the corresponding quarter ended 30/09/2021 and the corresponding period from 01/07/2021 to 30/09/2021, as reported in these financial results have been approved by the Parent's Board of Directors.

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.


3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of its subsidiary Medgel Private Limited.

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review report of its subsidiary, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. Our conclusion is not modified in respect of this matter.



7. The consolidated unaudited financial results includes the interim financial statements/ financial information/ financial results of Medgel Private Limited (subsidiary) which have not been reviewed/audited by their auditors, whose interim consolidated financial statements/ financial information/ financial results reflect total revenue of Rs. 1744.48 Lakhs, total net profit/(loss) after tax of Rs. 318.67 Lakhs and total comprehensive income of Rs. 83.74 Lakhs for the quarter ended 30/09/2021, as considered in the consolidated unaudited financial results. According to the information and explanations given to us by the Management, these interim financial statements / financial information / financial results are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matter.


Place: Indore

Date: 10/11/2021

UDIN: 21429040AAAAGN9172

For: Rawka & Associates
Chartered Accountants




Venus Rawka
(Partner)

M.No. 429040

FRN: 021606C

MEDI-CAPS LIMITED


REGD. OFFICE: MHOW-NEEMUCH ROAD, SECTOR-I,PITHAMPUR-454775, DISTT, DHAR (M.P.), Tel: 07292-256205, Fax: 0731-4041435

Website: www.medicaps.com Email: investors@medicaps.com CIN: L70100MP1983PLC002231

Statement of Unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year ended 30th September 2021

(Amount in Lacs except EPS)


Sr. No.	Particulars	Standalone						Consolidated					
		Quarter Ended			Half Year Ended		Year Ended	Quarter Ended			Half Year Ended		Year Ended
		3 Month Ended 30/09/2021	Preceding 3 Month Ended 30/06/2021	Corresponding 3 months ended in the previous year (30/09/2020)	Year to date figures for current period ended (30/09/2021)	Year to date figures for the previous year ended (30/09/2020)	Previous Year ended March 31 2021	3 Month Ended 30/09/2021	Preceding 3 Month Ended 30/06/2021	Corresponding 3 months ended in the previous year (30/09/2020)	Year to date figures for current period ended (30/09/2021)	Year to date figures for the previous year ended (30/09/2020)	Previous Year ended March 31 2021
(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)		
I	Revenue from operations												
	(a) Net sales	0.00	0.00	0.00	0.00	0.00	0.00	1722.41	1717.94	1476.59	3440.35	5741.57	
	(b) Other operating income	0.02	0.00	0.00	0.02	0.00	0.00	9.00	4.10	7.00	13.10	130.33	
I	Total income from operation	0.02	0.00	0.00	0.02	0.00	0.00	1731.40	1722.03	1483.58	3453.44	5871.89	
II	Other Income	1.64	1.27	0.00	2.91	0.00	0.00	13.08	12.37	3.62	25.45	5871.89	
III	Total Revenue (I+II)	1.66	1.27	0.00	2.93	0.00	0.00	1744.48	1734.40	1487.20	3478.89	5930.26	
IV	Expenses												
	a) Cost of material consumed	0.00	0.00	0.00	0.00	0.00	0.00	689.19	802.38	833.70	1491.57	3107.60	
	b) Purchase of stock in trade	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00	24.38	58.60	-141.42	83.18	-171.32	
	d) Employee benefits expense	4.74	4.13	0.00	8.87	0.00	0.00	191.38	164.38	171.49	355.76	670.99	
	e) Finance costs	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
	f) Power Cost	0.00	0.00	0.00	0.00	0.00	0.00	93.66	45.96	66.18	139.62	256.47	
	g) Depreciation and amortisation expense	5.43	5.44	0.00	10.87	0.00	0.00	47.34	47.34	37.31	94.68	152.11	
	h) Other expenses	2.37	4.02	0.00	6.39	0.00	0.00	375.62	287.75	207.58	663.37	790.43	
	Total Expenses (IV)	12.54	13.58	0.00	26.13	0.00	0.00	1421.77	1406.41	1174.83	2828.18	4806.28	
V	Profit / (Loss) before exceptional item and Extra Ordinary items & tax (III-IV)	-10.89	-12.32	0.00	-23.21	0.00	0.00	322.71	327.99	312.37	650.71	1123.98	
VI	Exceptional & Extraordinary Items	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
VII	Profit/(Loss) before tax (V-VI)	-10.89	-12.32	0.00	-23.21	0.00	0.00	322.71	327.99	312.37	650.71	1123.98	
VIII	Tax expense												
	a) Current Tax	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
	b) Deferred Tax	0.00	0.00	0.00	0.00	0.00	(0.51)	0.00	0.00	0.00	0.00	(0.51)	
	Total Tax Expenses	0.00	0.00	0.00	0.00	0.00	(0.51)	0.00	0.00	0.00	0.00	(0.51)	
IX	Profit (Loss) for the period from continuing operations (VII-VIII)	-10.89	-12.32	0.00	-23.21	0.00	0.51	322.71	327.99	312.37	650.71	1124.49	
X	Profit/(loss) from discontinued operations	-4.03	6.83	(5.14)	2.80	(32.59)	(11.59)	-4.03	6.83	-5.14	2.80	(11.59)	
XI	Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
XII	Profit/(loss) from Discontinued operations (after tax) (X-XI)	(4.03)	6.83	(5.14)	2.80	(32.59)	(11.59)	-4.03	6.83	(5.14)	2.80	(11.59)	
XIII	Share of profit (loss) of associates and joint ventures accounted for using equity method	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
XIV	Profit/(loss) for the period (IX+XII)	(14.92)	(5.49)	(5.14)	(20.41)	(32.59)	(11.08)	318.67	334.82	307.24	653.50	1112.90	
XV	Other comprehensive income												
	(a) (i) items that will not be reclassified to statement of profit & loss	39.10	26.09	24.29	65.19	57.46	123.47	83.74	65.33	52.56	149.07	262.88	
	(ii) Income tax on items that will not to be reclassified to statement of P& L	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
	(b) (i) items that will be reclassified to statement of profit & loss	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
	(ii) Income tax on items that will be reclassified to statement of P& L	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
	Other comprehensive income :	39.10	26.09	24.29	65.19	57.46	123.47	83.74	65.33	52.56	149.07	262.88	
	Total Comprehensive income for the period (Comprising Profit or Loss and other Comprehensive income for the period)	24.18	20.60	19.15	44.78	24.87	112.39	402.42	400.15	359.80	802.58	1375.78	
XVI	Total profit or loss, attributable to												
XVII	Profit or loss, attributable to owners of parent	0.00	0.00	0.00	0.00	0.00	0.00	318.67	334.82	307.24	653.50	1112.90	



[Handwritten signature]

	Total profit or loss, attributable to non-controlling interests	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
XVIII	Total Comprehensive income for the period attributable to												
	Comprehensive income for the period attributable to owners of parent	0.00	0.00	0.00	0.00	0.00	0.00	402.42	400.15	359.80	802.58	643.62	1375.78
	Total comprehensive income for the period attributable to owners of parent non-controlling interests	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
XIX	Paid-up equity share capital of the company (Face value Rs. 10/- Per Share)	1247.00	1247.00	1247.00	1247.00	1247.00	1247.00	1247.00	1247.00	1247.00	1247.00	1247.00	1247.00
XX	Reserves excluding revaluation reserves	0.00	0.00	0.00	0.00	0	4849.91	0.00	0.00	0.00	0.00	0.00	9224.24
XXI	Earnings per equity share (for continuing operation)												
	a) Basic	-0.09	-0.10	0.19	-0.19	0.46	0.99	2.59	2.63	2.93	5.22	5.42	11.13
	a) Diluted	-0.09	-0.10	0.19	-0.19	0.46	0.99	2.59	2.63	2.93	5.22	5.42	11.13
XXI	Earnings per equity share (for discontinued operation)												
	a) Basic	-0.03	0.05	(0.04)	0.02	(0.26)	(0.09)	(0.03)	0.05	(0.04)	0.02	(0.26)	(0.09)
	a) Diluted	-0.03	0.05	(0.04)	0.02	(0.26)	(0.09)	(0.03)	0.05	(0.04)	0.02	(0.26)	(0.09)
XXI	Earnings per equity share (for discontinued and continuing operation)												
	a) Basic	-0.12	-0.05	0.15	-0.16	0.20	0.90	2.56	2.68	2.89	5.24	5.16	11.04
	a) Diluted	-0.12	-0.05	0.15	-0.16	0.20	0.90	2.56	2.68	2.89	5.24	5.16	11.04

DATE : 10/11/2021
PLACE : INDORE

For and on behalf of the Board
MEDI-CAPS LIMITED

ALOK K GARG
MANAGING DIRECTOR
DIN: 00274321



2 The Un-audited standalone and Consolidated Statement of Assets & Liabilities as at 30th September, 2021 is as under:


(Amount in Lacs)

Particulars	Standalone		Consolidated	
	As at		As at	
	AS AT 30-09-2021 (Unaudited)	AS AT 31-03-2021 (Audited)	AS AT 30-09-2021 (Unaudited)	AS AT 31-03-2021 (Audited)
I. Assets				
(1) Non-Current Assets				
a) Tangible Assets				
(i) Property, Plant and Equipment	308.53	325.51	2909.25	2998.24
b) Intangible Assets				
(i) Goodwill	0.00	0.00	2814.15	2814.15
(c) Capital work-in-progress	0.00	0.00	221.58	54.22
(d) Investment Property	0.00	0.00	0.00	0.00
(e) Financial Assets				
(i) Investments	4389.96	4409.73	303.36	311.92
(f) Other non-current assets	5.09	5.15	38.76	36.59
Sub-total- Non-Current Assets	4703.58	4740.38	6287.10	6215.13
(2) Current assets				
(a) Inventories	4.94	4.94	749.34	670.61
(b) Financial Assets				
(i) Investments	1109.18	1028.99	2838.63	2629.56
(ii) Trade receivables	223.66	241.10	787.94	638.66
(iii) Cash and cash equivalents	0.16	0.20	0.46	0.22
(iv) Bank balances other than (iii) above	91.35	72.59	1000.46	680.68
(c) Other current assets	175.73	175.45	643.57	647.03
Sub-total- Current Assets	1605.00	1523.26	6020.41	5266.75
Total Assets	6308.58	6263.65	12307.51	11481.88
II. EQUITY AND LIABILITIES				
EQUITY				
(a) Equity Share Capital	1247.00	1247.00	1247.00	1247.00
(b) Other Equity	4894.69	4849.91	10026.82	9224.24
Sub-total- Equity	6141.69	6096.90	11273.81	10471.24
Non Controlling Assets	0.00	0.00	0.00	0.00
LIABILITIES				
(1) Non-Current Liabilities				
(a) Financial Liabilities	0.00	0.00	0.00	0.00
(b) Provisions	13.48	13.48	40.63	40.91
(c) Deferred tax liabilities (Net)	42.69	42.69	42.69	42.69
Sub-total- Non Current Liabilities	56.17	56.17	83.31	83.60
(2) Current Liabilities				
(a) Financial Liabilities	0.00	0.00	0.00	0.00
(i) Borrowings	0.00	0.00	0.00	0.00
(ii) Trade payables				
a) total outstanding dues of micro enterprises and small enterprises, and				
b) total outstanding dues of creditor other than micro enterprises and small enterprises;	3.56	3.47	529.26	615.52
(iii) Other financial liabilities (other than those specified in item (b),	0.00	0.00	0.00	0.00
(b) Other current liabilities	107.17	107.10	421.12	311.52
(c) Provisions	0.00	0.00		
(d) Current Tax Liabilities (Net)	0.00	0.00	0.00	0.00
Sub-total- Current Liabilities	110.73	110.57	950.38	927.04
Total Equity and Liabilities	6308.58	6263.65	12307.51	11481.88

DATE : 10/11/2021
PLACE : INDORE

For and on behalf of the Board
MEDI-CAPS LIMITED

ALOK K GARG
MANAGING DIRECTOR
DIN: 00274321



MEDI-CAPS LIMITED

REGD. OFFICE: MHOW-NEEMUCH ROAD, SECTOR-1,PITHAMPUR-454775, DISTT. DHAR (M.P.), Tel: Tel: 07292-256205, Fax: 0731-4041435

Website: www.medicaps.com Email: investors@medicaps.com CIN: L70100MP1983PLC002231


Reporting of Segment wise Revenue, Results and Capital Employed for quarter and half year ended 30th September 2021

(Amount in Lakhs)


S.No.	Segment Revenue	Quarter Ended			Half Year Ended		Year Ended
		3 Month Ended 30/09/2021	Preceding 3 Month Ended 30/06/2021	Corresponding 3 months ended in the previous year (30/09/2020)	Year to date figures for current period ended (30/09/2021)	Year to date figures for the previous year ended (30/09/2020)	Previous Year ended March 31 2021
		unaudited	unaudited	unaudited	unaudited	unaudited	Audited
1	Segment Revenue						
	Pharma Division	1,742.86	1,733.13	1,487.20	3,475.99	2,735.23	5,930.26
	Real Estate Division	1.64	1.27	0.00	2.91	0.00	0.00
	Other	0.00	0.00	0.00	0.00	0.00	0.00
	Gross Turnover	1,744.48	1,734.40	1,487.20	3,478.89	2,735.23	5,930.26
2	Segment Results						
	Pharma Division	333.59	340.31	312.38	673.91	550.54	1,123.98
	Real Estate Division	(10.89)	(12.32)	0.00	(23.21)	0.00	0.00
	Other	0.00	0.00	0.00	0.00	0.00	0.00
	Total Segment Profit Before Tax	322.71	327.99	312.38	650.71	550.54	1,123.98
	Interest Income	0.00	0.00	0.00	0.00	0.00	0.00
	Interest Expenses	0.00	0.00	0.00	0.00	0.00	0.00
	Other Unallocable Income net of Expenditure	0.00	0.00	0.00	0.00	0.00	0.00
	Profit Before Tax	322.71	327.99	312.38	650.71	550.54	1,123.98
3	Capital Employed						
	Segment Assets (A)						
	Pharma Division	12,006.04	11,695.98	10,666.54	12,006.04	10,666.54	11,381.88
	Real Estate Division	301.47	100.00	25.00	301.47	25.00	100.00
	Other	0.00	0.00	0.00	0.00	0.00	0.00
	Total (A)	12,307.51	11,795.98	10,691.54	12,307.51	10,691.54	11,481.88
	Segment Liabilities (B)						
	Pharma Division	933.70	824.60	927.88	933.70	927.88	910.64
	Real Estate Division	100.00	100.00	25.00	100.00	25.00	100.00
	Other	0.00	0.00	0.00	0.00	0.00	0.00
	Total (B)	1,033.70	924.60	952.88	1,033.70	952.88	1,010.64
4	Total Capital Employed (Segment Assets- Segment Liabilities)						
	Pharma Division	11,072.34	10,871.38	9,738.66	11,072.34	9,738.66	10,471.24
	Real Estate Division	201.47	0.00	0.00	201.47	0.00	0.00
	Other	0.00	0.00	0.00	0.00	0.00	0.00
	Total Capital Employed (Segment Assets- Segment Liabilities)	11,273.81	10,871.38	9,738.66	11,273.81	9,738.66	10,471.24

DATE : 10/11/2021
PLACE : INDORE

For and on behalf of the Board
MEDI-CAPS LIMITED



ALOK K GARG
MANAGING DIRECTOR
DIN: 00274321



MEDI-CAPS LIMITED

REGD. OFFICE: MHOW-NEEMUCH ROAD, SECTOR-1, PITHAMPUR-454775, DISTT. DHAR (M.P.), Tel: 07292-256205, Fax: 0731-404143

Website: www.Medicaps.com Email: investors@medicaps.com CIN: L70100MP1983PLC002231

Statement of Standalone and Consolidated cash flows for the half year ended 30th September 2021


(Amount in Lakhs)

PARTICULARS	Standalone		Consolidated	
	HALF YEAR ENDED ON 30.09.2021	HALF YEAR ENDED ON 30.09.2020	HALF YEAR ENDED ON 30.09.2021	HALF YEAR ENDED ON 30.09.2020
	Unaudited	Unaudited	Unaudited	Unaudited
A. Cash Flow from Operating Activities				
Net Profit before Tax & Extraordinary Items	-23.21	0.00	650.71	550.54
Adjustment For:				
Depreciation	16.56	0.00	100.36	74.62
Dividend Income	0.00	0.00	0.00	0.00
Other Comprehensive Income	65.19	0.00	149.07	68.20
Loss from Discontinue Operation	2.80	0.00	2.80	0.00
Operating Profit before Working Capital Change	61.34	(0.00)	902.94	693.37
Ajustment for Working Capital	0.00	0.00	0.00	
(Increase)/ Decrease in Sundry Debtors	17.44	0.00	(149.28)	-178.09
(Increase)/ Decrease in Inventories	0.00	0.00	(78.74)	-271.84
(Increase)/ Decrease in Loans & Advances	-0.22	0.00	3.51	-68.57
Increase in Current Liabilities & Provisions	0.15	0.00	23.06	556.93
Cash Generated from Working Capital	17.37	0.00	(201.46)	38.43
Cash generated from Operation	78.71	(0.00)	701.48	731.80
Net Income Tax Paid	0.00	0.00	0.00	0.00
Net cash Flow from Operating Activity	78.71	(0.00)	701.48	731.80
B. Cash Flow from Investing Activities				
Proceed from Sale/purchase of Fixed Assets	0.42	0.00	(178.72)	(10.32)
Purchase of Investment	(60.42)	0.00	(202.74)	(190.20)
Dividend Received	0.00	0.00	0.00	0.00
Discontinue Operation		(6.84)		-6.84
Net Cash used in Investing Activities	(60.00)	(6.84)	(381.46)	(207.36)
C. Cash Flow from Financial Activities				
Increase in Short term bank borrowing	0.00			
Increase in Long term borrowing	0.00	25.00	0.00	25.00
Net Cash Used in Financial Activities	0.00	25.00	0.00	25.00
Net Increase in Cash and Cash Equivalents (A+B+C)	18.71	18.16	320.02	549.44
Cash & Cash Equivalents at the				
Beginning of the year	72.79	74.52	680.90	125.28
Closing of the year	91.50	92.68	1000.92	674.72
Increase in Cash and Cash Equivalents	18.71	18.16	320.02	549.44


Note: This Cash flow statement is belongs to Continue and Discontinue operation both for this half yearly result

Date : 10/11/2021
Place: INDORE

For and on behalf of Board
MEDI-CAPS LIMITED



ALOK K GARG
MANAGING DIRECTOR
DIN : 00274321




NOTES:

1. The above unaudited results for the Quarter and half year ended Sept. 30, 2021 were reviewed and recommended by the Audit Committee and approved by the Board of Directors in its meeting held on November 10, 2021. The above results have been reviewed by statutory Auditors of the company in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, who have expressed an unmodified opinion. The Company's Management has exercised necessary due diligence to ensure that the financial results provide a true and fair view of its affairs.
2. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
3. The above consolidated results included the result of wholly owned subsidiary company i.e. Medgel Private Limited.
4. The Company has two reportable segments for the Consolidated Financial Statements which consists Pharma division and Real Estate division in accordance with Ind AS-108 Operating Segment and same is enclosed with this result.
5. The figures of the previous period / year have been re-stated/ re-grouped / re-arranged/ reclassified and / or recasted wherever found necessary.
6. The aforesaid Un-audited financial Results will be uploaded on the Company's website www.medicaps.com and will also be available on the websites of the Stock exchange i.e. www.bseindia.com for the benefit of shareholders and investors.
7. On 21st Nov., 2019, the company announced to permanently discontinue Company's operations related to production/manufacturing of Hard Gelatin Capsule Shell. The discontinuation is consistent with the Company's long-term strategy to focus its activities in the areas of Real Estate Business and to divest unrelated activities. Accordingly, Loss for the quarter ended Sept. 30, 2021 is from discontinuing operation.
8. Description of Income & Expenditure of Discontinue operations

(Amount in Lakhs)


Particulars	3 Month Ended	3 Months Ended	6 Months Ended
	30.09.2021	30.06.2021	30.09.2021
I Income from operations	0.00	0.00	0.00
II Other Income	0.24	11.12	11.36
III Total income (I+II)	0.24	11.12	11.36
IV Expenses			
a) Changes in Inventories of finished goods, &	0.00	0.00	0.00



	work in progress			
	b) Employee benefits expense	0.00	0.00	0.00
	c) Finance Cost	0.00	0.00	0.00
	d) Depreciation expense	2.84	2.84	5.68
	e) Other expenses	1.43	1.45	2.88
	Total Expenses (IV)	4.27	4.29	8.56
V	Net Profit/Loss From Discontinue Operation	-4.03	6.83	2.80

DATE : 10/11/2021
PLACE: INDORE

for and on behalf of the Board
MEDI-CAPS LIMITED



ALOK K GARG
MANAGING DIRECTOR
DIN: 00274321

